These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21714066)

  • 1. Markers for microvascular invasion in hepatocellular carcinoma: where do we stand?
    Gouw AS; Balabaud C; Kusano H; Todo S; Ichida T; Kojiro M
    Liver Transpl; 2011 Oct; 17 Suppl 2():S72-80. PubMed ID: 21714066
    [No Abstract]   [Full Text] [Related]  

  • 2. Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation.
    Kneteman N; Livraghi T; Madoff D; de Santibañez E; Kew M
    Liver Transpl; 2011 Oct; 17 Suppl 2():S117-27. PubMed ID: 21584926
    [No Abstract]   [Full Text] [Related]  

  • 3. Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma?
    Yao FY; Breitenstein S; Broelsch CE; Dufour JF; Sherman M
    Liver Transpl; 2011 Oct; 17 Suppl 2():S109-16. PubMed ID: 21584927
    [No Abstract]   [Full Text] [Related]  

  • 4. Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation?
    Grant D; Fisher RA; Abecassis M; McCaughan G; Wright L; Fan ST
    Liver Transpl; 2011 Oct; 17 Suppl 2():S133-8. PubMed ID: 21634006
    [No Abstract]   [Full Text] [Related]  

  • 5. Selection criteria for patients with hepatocellular carcinoma in liver transplantation.
    Kaido T; Takada Y; Uemoto S
    Transplantation; 2009 Aug; 88(3):442-3; author reply 443. PubMed ID: 19667951
    [No Abstract]   [Full Text] [Related]  

  • 6. Histologic Grade and Mitotic Index as Predictors of Microvascular Invasion in Hepatocellular Carcinoma.
    Osório FM; Vidigal PV; Ferrari TC; Lima AS; Lauar GM; Couto CA
    Exp Clin Transplant; 2015 Oct; 13(5):421-5. PubMed ID: 26221994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifocal manifestation does not affect vascular invasion of hepatocellular carcinoma: implications for patient selection in liver transplantation.
    Löhe F; Angele MK; Rentsch M; Graeb C; Gerbes A; Löhrs U; Beuers U; Jauch KW
    Clin Transplant; 2007; 21(6):696-701. PubMed ID: 17988261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which matters most: number of tumors, size of the largest tumor, or total tumor volume?
    Germani G; Gurusamy K; Garcovich M; Toso C; Fede G; Hemming A; Suh KS; Weber A; Burroughs AK
    Liver Transpl; 2011 Oct; 17 Suppl 2():S58-66. PubMed ID: 21584928
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of recurrent hepatocellular carcinoma after liver transplantation.
    Davis E; Wiesner R; Valdecasas J; Kita Y; Rossi M; Schwartz M
    Liver Transpl; 2011 Oct; 17 Suppl 2():S162-6. PubMed ID: 21688382
    [No Abstract]   [Full Text] [Related]  

  • 10. Liver Transplant for Hepatocellular Carcinoma: Pathologic Point Of View.
    Özgün G; Haberal Reyhan N; Özdemir BH; Haberal M
    Exp Clin Transplant; 2017 Mar; 15(Suppl 2):50-54. PubMed ID: 28301999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation?
    Olthoff KM; Forner A; Hübscher S; Fung J
    Liver Transpl; 2011 Oct; 17 Suppl 2():S26-33. PubMed ID: 21656653
    [No Abstract]   [Full Text] [Related]  

  • 12. Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision.
    Bruix J; Fuster J; Llovet JM
    Liver Transpl; 2003 Jul; 9(7):700-2. PubMed ID: 12827556
    [No Abstract]   [Full Text] [Related]  

  • 13. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma.
    Reddy MS; Manas DM
    Transplantation; 2007 Feb; 83(3):367-8. PubMed ID: 17297420
    [No Abstract]   [Full Text] [Related]  

  • 14. Pathology of combined hepatocellular-cholangiocarcinoma.
    Yeh MM
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1485-92. PubMed ID: 20796144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of soluble transferrin receptors study in hepatocellular carcinoma with underlying cirrhosis.
    Mehta R; Suvarna D; Mustafa CP; Sadasivan S
    Indian J Cancer; 2005; 42(4):215. PubMed ID: 16391443
    [No Abstract]   [Full Text] [Related]  

  • 16. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria.
    Lim KC; Chow PK; Allen JC; Chia GS; Lim M; Cheow PC; Chung AY; Ooi LL; Tan SB
    Ann Surg; 2011 Jul; 254(1):108-13. PubMed ID: 21527845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma and liver transplantation.
    Washburn K; Halff G
    Curr Opin Organ Transplant; 2011 Jun; 16(3):297-300. PubMed ID: 21505342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of microvascular invasion before curative resection of hepatocellular carcinoma.
    Kim BK; Han KH; Park YN; Park MS; Kim KS; Choi JS; Moon BS; Chon CY; Moon YM; Ahn SH
    J Surg Oncol; 2008 Mar; 97(3):246-52. PubMed ID: 18095300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma.
    Llovet JM; Paradis V; Kudo M; Zucman-Rossi J
    Liver Transpl; 2011 Oct; 17 Suppl 2(Suppl 2):S67-71. PubMed ID: 21594967
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunosuppression and hepatocellular carcinoma.
    Schlitt HJ; Mornex F; Shaked A; Trotter JF
    Liver Transpl; 2011 Oct; 17 Suppl 2():S159-61. PubMed ID: 21506251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.